Olympia Pharmaceuticals
Olympia Pharmaceuticals (Orlando, FL). Historically also Lowlite Investments, Inc. d/b/a Olympia Pharmacy · Orlando, FL
We do not sell medication and we have no commercial relationship with Olympia Pharmaceuticals. Everything below is either published by a regulator or published by the pharmacy about itself, labelled as such and dated. We give you the official lookups rather than asking you to take our word for the current position.
The short answer
- Olympia Pharmaceuticals is the trading name of Olympia Pharmaceuticals (Orlando, FL). Historically also Lowlite Investments, Inc. d/b/a Olympia Pharmacy, based in Orlando, FL. Regulators file under the legal name, so search that.
- Registration: 503B. Olympia Pharmaceuticals operates as an FDA-registered 503B outsourcing facility in Orlando, which means FDA cGMP requirements apply and the site is subject to routine FDA inspection. Read the name carefully: the records below belong to two related but distinct registrants, and treating them as one company would misstate both.
- FDA warning letter: FLA-14-04 (February 18, 2014). Read the dates and which site each one covers — both are material.
- Compounded semaglutide and tirzepatide are NOT FDA-approved as finished products, whichever pharmacy prepares them. FDA does not review them for safety, effectiveness or manufacturing quality.
Registration and licence
Olympia Pharmaceuticals operates as an FDA-registered 503B outsourcing facility in Orlando, which means FDA cGMP requirements apply and the site is subject to routine FDA inspection. Read the name carefully: the records below belong to two related but distinct registrants, and treating them as one company would misstate both.
Regulatory record
Every item below is a public document, linked to its source, with the date it was issued and the dates of any inspection behind it. Where the agency recorded the company's response, a completed recall, or which legal entity a record actually concerns, that is included — leaving it out would misrepresent the record. Where the company has answered publicly, its answer is printed too.
- FDA Form 483 (observations)Form 483, Olympia Pharmaceuticals, Orlando FL outsourcing facility
From an inspection running 2025-07-28 to 2025-08-08.
Investigator observations included aseptic-process validation the report considered inadequate — air-visualization studies showing air arching over stoppers, caps and seals so that critical components did not receive first air — written production and process-control procedures the report found insufficient, and cleaning practices in the aseptic area, including operators contacting previously disinfected interior surfaces and a package of wipes left open to the ISO-7 cleanroom.
Which entity this concerns: Concerns the Olympia Pharmaceuticals 503B outsourcing facility in Orlando.
Context FDA published with it: A Form 483 is a list of an investigator’s observations. FDA states on the form itself that observations do not represent a final agency determination regarding compliance.
Our check on July 29, 2026 did not surface a published close-out. That means we did not find one, not that none exists.
Read it on fda.gov - Voluntary recallVoluntary nationwide recall, 11 lots
Olympia Pharmacy voluntarily recalled 11 lots of compounded injectables to the consumer level — Trimix formulas F-9, T-105 and SB-4, Sermorelin, Sincalide, Hydroxocobalamin and NAD — because they were found to be out of specification. None of the recalled products was a GLP-1.
Context FDA published with it: The company announcement records that it had received no reports or concerns from patients about the safety of the recalled products, and that no patient had reported an adverse event attributed to them. The recall was voluntary and the company arranged return and replacement.
Our check on July 29, 2026 did not surface a published close-out. That means we did not find one, not that none exists.
Read it on fda.gov - FDA warning letterFLA-14-04
From an inspection running 2013-03-04 to 2013-03-21.
FDA found the firm was not receiving valid prescriptions for individually identified patients for a portion of what it produced, was compounding domperidone — which is not the subject of a USP or NF monograph, not a component of an FDA-approved drug and not on the 503A bulks list — and recorded serious deficiencies in its practices for producing sterile drug products.
Which entity this concerns: Addressed to Lowlite Investments, Inc. d/b/a Olympia Pharmacy at 6700 Conroy Windermere Rd, Orlando — a different address and registrant from the Olympia Pharmaceuticals outsourcing facility. It is more than a decade old and predates the current facility. We include it because it is public and because omitting a company’s regulatory history would be its own kind of editing.
Context FDA published with it: All sterile products produced before 27 March 2013 were recalled as a result of the inspection observations.
Our check on July 29, 2026 did not surface a published close-out. That means we did not find one, not that none exists.
Read it on fda.gov
What it compounds for GLP-1 patients
- · Compounded semaglutide
- · Compounded tirzepatide
Compounded semaglutide and tirzepatide are not FDA-approved as finished drug products. FDA does not review them for safety, effectiveness or manufacturing quality before they reach patients. That applies to every compounded GLP-1 regardless of which pharmacy prepares it, and it is a separate question from whether the pharmacy is licensed.
If you would rather not take that trade, the FDA-approved oral products now start at $149/month direct from their manufacturers — see the cheapest routes compared.
Check it yourself
Search under the legal name — Olympia Pharmaceuticals (Orlando, FL). Historically also Lowlite Investments, Inc. d/b/a Olympia Pharmacy — not the brand. Regulators file under the legal entity, and searching the trading name alone is how records get missed.
- FDA — Registered Outsourcing Facilities (503B)
The authoritative list of pharmacies registered with the FDA as 503B outsourcing facilities (the higher-oversight compounding tier). If a pharmacy claims to be 503B, it should appear here.
- FDA — 503A vs 503B explainer
What the two compounding categories mean: 503A = patient-specific prescriptions under state board oversight; 503B = larger-batch outsourcing facilities under direct FDA cGMP inspection.
- FDA — Warning Letters search
Search the FDA’s public warning-letter database by company name to see whether a pharmacy has an open compliance action. Confirm the date and status — letters can be resolved.
- NABP — Verify a pharmacy / .pharmacy
The National Association of Boards of Pharmacy tools flag rogue online pharmacies and list accredited ones. Legitimate US pharmacies are licensed by a state board.
- LegitScript — Certification lookup
LegitScript certifies healthcare merchants that meet legal + safety standards. Many reputable telehealth GLP-1 providers display a LegitScript badge you can verify here.
- Your state Board of Pharmacy
Every US pharmacy must be licensed by the state board where it operates (and often where it ships). State boards publish license status + disciplinary history.
Questions people ask about Olympia Pharmaceuticals
Is Olympia Pharmaceuticals a licensed pharmacy?
We have not been able to verify a published state licence record for Olympia Pharmaceuticals. Use your state board of pharmacy's lookup to check before buying.
What is the regulatory record for Olympia Pharmaceuticals?
FDA issued warning letter FLA-14-04 on February 18, 2014, following an inspection running 2013-03-04 to 2013-03-21. FDA found the firm was not receiving valid prescriptions for individually identified patients for a portion of what it produced, was compounding domperidone — which is not the subject of a USP or NF monograph, not a component of an FDA-approved drug and not on the 503A bulks list — and recorded serious deficiencies in its practices for producing sterile drug products. All sterile products produced before 27 March 2013 were recalled as a result of the inspection observations. Our check on July 29, 2026 did not surface a published close-out letter, which means we did not find one — not that none exists.
Is a Form 483 the same as a warning letter?
No, and the difference matters. A Form 483 is the list of observations an FDA investigator leaves at the end of an inspection. It records what the investigator saw, not an agency finding that the law was broken. A warning letter comes later and states FDA's position that violations occurred. Firms respond to 483s and many are resolved without a warning letter ever being issued.
Does Olympia Pharmaceuticals make FDA-approved GLP-1 medication?
No compounding pharmacy does. Olympia Pharmaceuticals publicly compounds compounded semaglutide and compounded tirzepatide. Compounded drugs are not FDA-approved: the agency does not review them for safety, effectiveness or manufacturing quality before they reach patients. That is true of every compounded product regardless of which pharmacy prepares it, and it is a different thing from the pharmacy being licensed or unlicensed.
How do I check Olympia Pharmaceuticals myself?
Three free lookups settle it: the FDA warning-letter database, searched by the legal name (Olympia Pharmaceuticals (Orlando, FL). Historically also Lowlite Investments, Inc. d/b/a Olympia Pharmacy) rather than the trading name; the FDA list of registered 503B outsourcing facilities, if the pharmacy claims 503B status; and your state board of pharmacy's licence verification. All three are linked at the bottom of this page. Check the legal name — regulators file under it, and searching the brand alone misses records.